^
    CANCER:

    Fibrosarcoma





    Show legend
    Group by Gene:
    Include preclinical:

    0
    PD1 inhibitor
    pembrolizumab
    camrelizumab
    1
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    2
    mTOR inhibitor
    temsirolimus
    everolimus
    3
    ALK inhibitor
    crizotinib
    ceritinib
    4
    BRAF inhibitor, BRAF V600E inhibitor
    vemurafenib
    5
    PRMT5 inhibitor
    MRTX1719
    6
    Multi-tyrosine kinase inhibitor
    cabozantinib tablet
    anlotinib
    7
    PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
    imatinib
    8
    TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
    entrectinib
    9
    WEE1 inhibitor
    AZD1775
    10
    Bifunctional alkylating agent, Topoisomerase II inhibitor
    doxorubicin hydrochloride + ifosfamide
    11
    Topoisomerase II inhibitor, Tubulin polymerization inhibitor, RNA synthesis inhibitor
    vincristine + dactinomycin
    12
    Bifunctional alkylating agent, Topoisomerase II inhibitor, DNA synthesis inhibitor
    cisplatin + ifosfamide + epirubicin
    13
    CD30-targeted antibody-drug conjugate, ALK inhibitor, Microtubule inhibitor
    crizotinib + brentuximab vedotin
    ceritinib + brentuximab vedotin
    14
    Glutamine antagonist, Nerve growth factor inhibitor
    DR6MP + JHU395
    15
    Nerve growth factor inhibitor
    DR6MP
    16
    CD122 agonist, IL-2 stimulant
    NKTR-214
    17
    MCSP inhibitor
    CSPG4.TNK
    18
    Chemotherapy
    VAC
    19
    c-MET inhibitor, MEK inhibitor
    MEK inhibitor + c-MET inhibitor
    No biomarker
    NTRK3 fusion
    NF2 E108X
    NF1 mutation + CDKN2A deletion + CDKN2B deletion + MTAP deletion
    TMB-H + PD-L1 overexpression
    BRAF V600E
    RBPMS-MET fusion
    NTRK2 fusion
    NTRK1 fusion
    TFG-ROS1 rearrangement
    NF1 mutation
    TP53 mutation
    TSC2 A736V
    SQSTM1-NTRK1 fusion
    ETV6-NTRK3 fusion
    TJP1-ROS1 fusion + NF1 mutation
    ALK1 rearrangement
    CD8 positive
    CSPG4 overexpression
    RANBP2-ALK rearrangement + TNFRSF8 expression